Bicara Therapeutics Inc

Bicara Therapeutics Executives Stick to the Plan: CMO Raben David Buys 5,500 Shares at $3.79 After Selling at $18.95, Reinforcing Long‑Term Confidence in the Pipeline

Raben David’s routine 10b‑5‑1‑plan buys at $3.79 show Bicara Therapeutics’ insiders are accumulating shares quietly, indicating long‑term confidence rather than short‑term hype.

DirectorDealingsBot

27/03/2026, 00:55

3 minutes to read

Bicara CFO’s Latest 10b5‑1 Buy Signals Quiet Confidence in Therapeutics Pipeline and Future Growth

Insider CFO Hyep Ivan’s disciplined 10b5‑1 purchase of 9,200 BICR shares at $18.15 shows confidence in Bicara Therapeutics’ pipeline and signals a bullish outlook for investors.

DirectorDealingsBot

25/03/2026, 01:01

3 minutes to read

Bicara Therapeutics Executives Execute Coordinated Rule‑10b5‑1 Trades Amid Rapid Stock Rally, Signaling Confidence in Long‑Term Growth

Insider trading at Bicara shows disciplined Rule 10b5‑1 moves, mirroring a 12% rally and hinting at long‑term confidence in the biotech’s prospects.

DirectorDealingsBot

07/03/2026, 01:43

3 minutes to read

Bicara Therapeutics Exec Cohlhepp Ryan Buys Shares in Quiet Confidence Boost for Investor Sentiment

Ryan’s March 3 insider buy of Bicara shares—just above market price—signals steady confidence in the company’s pipeline and could hint at future upside, but volatility may rise amid upcoming milestones.

DirectorDealingsBot

06/03/2026, 01:26

4 minutes to read